Tag: Multiple Sclerosis
Age of Onset May Affect Clinical Outcomes for MS Patients on DMT
Age-dependent differences seen for clinical outcomes in response to disease-modifying therapy
Early Treatment Tied to Less Disability With Pediatric-Onset MS
Less disability seen among those initiating disease-modifying therapy within two years of clinical onset
Comorbidities Tied to Higher Rates of All-Cause Admissions in MS Patients
But comorbidities not associated with increased hospitalizations related to multiple sclerosis
2011 to 2017 Saw Increase in Spending on DMTs for MS
Increase in annual expenditures on MS DMTs mainly driven by increases in per-prescription costs
Marijuana Use for MS Tied to Legal Permissiveness
Most patients have accurate knowledge about the legal status of cannabis where they live
Breastfeeding May Protect Against Postpartum Relapses in MS
Pooled summary odds ratio of 0.63 found for correlation of breastfeeding with relapse
More Girls Admitted With Pediatric Multiple Sclerosis
Highest admission rate seen in southern part of U.S.; number of admissions highest for white children
Evidence Uncertain Whether Interventions Prevent Falls in MS
There are few studies, most of which are small trials and of low quality because of study methods
Risk for Disability Worsening Increased for MS With Comorbid Depression
Risk increased for persons with depression defined by ICD-10, those exposed to antidepressants
MENACTRIMS Guidelines for Multiple Sclerosis Updated
IFN-beta, glatiramer acetate, teriflunomide, dimethyl fumarate can be started in treatment-naive patients
